Published in BMC Cancer on November 09, 2003
BET bromodomain inhibition as a novel strategy for reactivation of HIV-1. J Leukoc Biol (2012) 2.80
Immunomodulatory effects of deacetylase inhibitors: therapeutic targeting of FOXP3+ regulatory T cells. Nat Rev Drug Discov (2009) 2.00
Histone deacetylase inhibitors impair the elimination of HIV-infected cells by cytotoxic T-lymphocytes. PLoS Pathog (2014) 1.59
Valproic acid and other histone deacetylase inhibitors induce microglial apoptosis and attenuate lipopolysaccharide-induced dopaminergic neurotoxicity. Neuroscience (2007) 1.42
HDAC inhibitor reduces cytokine storm and facilitates induction of chimerism that reverses lupus in anti-CD3 conditioning regimen. Proc Natl Acad Sci U S A (2008) 1.41
Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer. Mol Med (2011) 1.41
Conditional deletion of histone deacetylase 1 in T cells leads to enhanced airway inflammation and increased Th2 cytokine production. J Immunol (2010) 1.39
Phase II study of belinostat in patients with recurrent or refractory advanced thymic epithelial tumors. J Clin Oncol (2011) 1.36
Histone/protein deacetylase inhibitors increase suppressive functions of human FOXP3+ Tregs. Clin Immunol (2010) 1.30
Histone acetylation is associated with differential gene expression in the rapid and robust memory CD8(+) T-cell response. Blood (2006) 1.26
HDAC inhibitors and neurodegeneration: at the edge between protection and damage. Pharmacol Res (2010) 1.15
Histone/protein deacetylases and T-cell immune responses. Blood (2012) 1.14
Trichostatin A and oncolytic HSV combination therapy shows enhanced antitumoral and antiangiogenic effects. Mol Ther (2008) 1.11
Histone deacetylase regulation of immune gene expression in tumor cells. Immunol Res (2008) 0.97
HDAC inhibitors and immunotherapy; a double edged sword? Oncotarget (2014) 0.97
Blocking TH17-polarizing cytokines by histone deacetylase inhibitors in vitro and in vivo. J Leukoc Biol (2008) 0.96
Enhancement of vaccinia virus based oncolysis with histone deacetylase inhibitors. PLoS One (2010) 0.95
The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients. Am J Hematol (2012) 0.94
Suberoylanilide hydroxamic acid induces limited changes in the transcriptome of primary CD4(+) T cells. AIDS (2013) 0.94
Neuroprotection by the histone deacetylase inhibitor trichostatin A in a model of lipopolysaccharide-sensitised neonatal hypoxic-ischaemic brain injury. J Neuroinflammation (2012) 0.92
Evaluating epigenetic landmarks in the brain of multiple sclerosis patients: a contribution to the current debate on disease pathogenesis. Prog Neurobiol (2008) 0.91
Effects of histone deacetylase inhibitor SAHA on effector and FOXP3+regulatory T cells in rhesus macaques. Transplant Proc (2008) 0.91
Attenuation of vascular dementia by sodium butyrate in streptozotocin diabetic rats. Psychopharmacology (Berl) (2011) 0.90
The therapeutic potential of HDAC inhibitors in the treatment of multiple sclerosis. Mol Med (2011) 0.90
Regulation of immune responses by histone deacetylase inhibitors. ISRN Hematol (2012) 0.90
Histone deacetylase 9 activates gamma-globin gene expression in primary erythroid cells. J Biol Chem (2010) 0.90
Inhibition of histone deacetylases in inflammatory bowel diseases. Mol Med (2011) 0.89
Butyrate-induced cell death and differentiation are associated with distinct patterns of ROS in HT29-derived human colon cancer cells. Dig Dis Sci (2009) 0.83
Overexpression screens identify conserved dosage chromosome instability genes in yeast and human cancer. Proc Natl Acad Sci U S A (2016) 0.82
Trichostatin differentially regulates Th1 and Th2 responses and alleviates rheumatoid arthritis in mice. J Clin Immunol (2011) 0.80
Coordinated histone H3 methylation and acetylation regulate physiologic and pathologic fas ligand gene expression in human CD4+ T cells. J Immunol (2014) 0.80
Histone deacetylase inhibitors prevent activation-induced cell death and promote anti-tumor immunity. Oncogene (2015) 0.79
HDAC activity is required for efficient core promoter function at the mouse mammary tumor virus promoter. J Biomed Biotechnol (2010) 0.79
Foxp3 inhibits HDAC1 activity to modulate gene expression in human T cells. Virology (2011) 0.79
Trichostatin A promotes the generation and suppressive functions of regulatory T cells. Clin Dev Immunol (2013) 0.79
Processing of DNA double strand breaks by alternative non-homologous end-joining in hyperacetylated chromatin. Genome Integr (2012) 0.77
A phase I trial of panobinostat (LBH589) in patients with metastatic melanoma. Cancer Med (2016) 0.76
SAHA, an HDAC inhibitor, synergizes with tacrolimus to prevent murine cardiac allograft rejection. Cell Mol Immunol (2012) 0.76
Roles of histone hypoacetylation in LAT expression on T cells and Th2 polarization in allergic asthma. J Transl Med (2013) 0.75
Modulation of Treg function improves adenovirus vector-mediated gene expression in the airway. Gene Ther (2014) 0.75
The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol (1996) 22.30
NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol (1998) 21.48
Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol (2000) 20.70
Determination of lymphocyte division by flow cytometry. J Immunol Methods (1994) 11.48
A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. Nature (1997) 9.71
Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet (1999) 9.53
Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J Biol Chem (1990) 9.21
Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. Cell (1997) 8.99
Alteration of nucleosome structure as a mechanism of transcriptional regulation. Annu Rev Biochem (1998) 8.86
Histone deacetylases associated with the mSin3 corepressor mediate mad transcriptional repression. Cell (1997) 7.64
Apoptosis signaling. Annu Rev Biochem (2000) 6.18
Helper T cell differentiation is controlled by the cell cycle. Immunity (1998) 5.71
Role of the histone deacetylase complex in acute promyelocytic leukaemia. Nature (1998) 5.63
Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells. J Natl Cancer Inst (2000) 5.21
A histone deacetylase corepressor complex regulates the Notch signal transduction pathway. Genes Dev (1998) 4.78
The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr (1996) 4.62
Transcriptional repression by YY1 is mediated by interaction with a mammalian homolog of the yeast global regulator RPD3. Proc Natl Acad Sci U S A (1996) 4.61
Butyrate inhibits inflammatory responses through NFkappaB inhibition: implications for Crohn's disease. Gut (2000) 4.32
The I kappa B kinase (IKK) and NF-kappa B: key elements of proinflammatory signalling. Semin Immunol (2000) 4.11
Histone methylation versus histone acetylation: new insights into epigenetic regulation. Curr Opin Cell Biol (2001) 3.86
B-cell surface antigen B7 provides a costimulatory signal that induces T cells to proliferate and secrete interleukin 2. Proc Natl Acad Sci U S A (1991) 3.84
Post-activation turn-off of NF-kappa B-dependent transcription is regulated by acetylation of p65. J Biol Chem (2002) 3.48
A synthetic inhibitor of histone deacetylase, MS-27-275, with marked in vivo antitumor activity against human tumors. Proc Natl Acad Sci U S A (1999) 3.26
Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL. Nat Genet (1998) 2.97
The antitumor histone deacetylase inhibitor suberoylanilide hydroxamic acid exhibits antiinflammatory properties via suppression of cytokines. Proc Natl Acad Sci U S A (2002) 2.91
Histone deacetylase inhibitors as new cancer drugs. Curr Opin Oncol (2001) 2.91
The histone deacetylase inhibitor SAHA arrests cancer cell growth, up-regulates thioredoxin-binding protein-2, and down-regulates thioredoxin. Proc Natl Acad Sci U S A (2002) 2.69
The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species. Proc Natl Acad Sci U S A (2001) 2.65
Chromatin remodeling, measured by a novel real-time polymerase chain reaction assay, across the proximal promoter region of the IL-2 gene. J Immunol (2001) 2.40
Intracellular hydrogen peroxide and superoxide anion detection in endothelial cells. J Leukoc Biol (1994) 2.32
IL-15 and IL-2: a matter of life and death for T cells in vivo. Nat Med (2001) 2.29
Modulation of p53, ErbB1, ErbB2, and Raf-1 expression in lung cancer cells by depsipeptide FR901228. J Natl Cancer Inst (2002) 2.06
Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. J Clin Invest (2001) 2.00
Role of covalent modifications of histones in regulating gene expression. Gene (1999) 1.92
Protein modules that manipulate histone tails for chromatin regulation. Nat Rev Mol Cell Biol (2001) 1.90
FR901228, a potent antitumor antibiotic, is a novel histone deacetylase inhibitor. Exp Cell Res (1998) 1.78
Differential display cloning of a novel human histone deacetylase (HDAC3) cDNA from PHA-activated immune cells. Biochem Biophys Res Commun (1998) 1.62
Hybrid polar histone deacetylase inhibitor induces apoptosis and CD95/CD95 ligand expression in human neuroblastoma. Cancer Res (1999) 1.51
Genes modulated by histone acetylation as new effectors of butyrate activity. FEBS Lett (2001) 1.44
Up-regulation of costimulatory/adhesion molecules by histone deacetylase inhibitors in acute myeloid leukemia cells. Blood (2000) 1.43
Trichostatin A reverses skewed expression of CD154, interleukin-10, and interferon-gamma gene and protein expression in lupus T cells. Proc Natl Acad Sci U S A (2001) 1.39
Inhibition of IL-8 gene expression in Caco-2 cells by compounds which induce histone hyperacetylation. Cytokine (1997) 1.30
CD28 and apoptosis. Curr Opin Immunol (1995) 1.26
The histone-deacetylase inhibitor Trichostatin A blocks proliferation and triggers apoptotic programs in hepatoma cells. J Hepatol (2002) 1.25
How cells die: apoptosis pathways. J Allergy Clin Immunol (2001) 1.24
The T-cell receptor signalosome: a dynamic structure with expanding complexity. Curr Opin Immunol (2002) 1.22
Histone deacetylase inhibitors as potential anti-skin cancer agents. Cancer Res (1999) 1.22
Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase. Oncogene (1999) 1.22
Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate. Br J Cancer (1999) 1.19
DNA methylation and histone deacetylation associated with silencing DAP kinase gene expression in colorectal and gastric cancers. Br J Cancer (2002) 1.17
IL-2 and related cytokines can promote T cell survival by activating AKT. J Immunol (2002) 1.16
Inhibition of histone deacetylase activity by trichostatin A modulates gene expression during mouse embryogenesis without apparent toxicity. Cancer Res (2001) 1.12
Histone deacetylase inhibitors suppress IL-2-mediated gene expression prior to induction of apoptosis. Blood (2000) 1.12
Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of daxx in acute promyelocytic leukaemia with t(15;17). Br J Haematol (2001) 1.12
Functional requirement for histone deacetylase 1 in Caenorhabditis elegans gonadogenesis. Mol Cell Biol (2002) 1.11
Functional consequences of costimulation by ICAM-1 on IL-2 gene expression and T cell activation. J Immunol (1998) 1.08
Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene (2001) 1.05
Antineoplastic action of 5-aza-2'-deoxycytidine and histone deacetylase inhibitor and their effect on the expression of retinoic acid receptor beta and estrogen receptor alpha genes in breast carcinoma cells. Cancer Chemother Pharmacol (2001) 1.03
Inhibition of mitogenesis in Balb/c-3T3 cells by Trichostatin A. Multiple alterations in the induction and activation of cyclin-cyclin-dependent kinase complexes. J Biol Chem (2000) 1.02
Trichostatin A modulates expression of p21waf1/cip1, Bcl-xL, ID1, ID2, ID3, CRAB2, GATA-2, hsp86 and TFIID/TAFII31 mRNA in human lung adenocarcinoma cells. Biol Chem (2000) 1.02
Histone hyperacetylation induced by histone deacetylase inhibitors is not sufficient to cause growth inhibition in human dermal fibroblasts. J Biol Chem (2001) 1.01
Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase. J Antibiot (Tokyo) (1996) 0.98
Bcl-2 expression regulates sodium butyrate-induced apoptosis in human MCF-7 breast cancer cells. Cell Growth Differ (1996) 0.97
Histone deacetylase inhibitors such as sodium butyrate and trichostatin A induce apoptosis through an increase of the bcl-2-related protein Bad. Brain Tumor Pathol (2001) 0.96
CTLA-4 ligation suppresses CD28-induced NF-kappaB and AP-1 activity in mouse T cell blasts. J Biol Chem (1999) 0.88
Histone acetylation is a checkpoint in FGF-stimulated mesoderm induction. Dev Dyn (2000) 0.87
Histone deacetylase inhibition results in decreased macrophage CD9 expression. Biochem Biophys Res Commun (2002) 0.86
Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors. Cancer Res (2002) 0.85
Role of CD80, CD86, and CTLA4 on mouse CD4(+) T lymphocytes in enhancing cell-cycle progression and survival after activation with PMA and ionomycin. J Leukoc Biol (2002) 0.83
Expression patterns of histone deacetylases in bovine oocytes and early embryos, and the effect of their inhibition on embryo development. Zygote (2001) 0.78
Chromatin-immune connections: regulation of MHC and other genes. J Reprod Immunol (2000) 0.77
Crystal structure of a soluble CD28-Fab complex. Nat Immunol (2005) 2.46
Bcl-3 and NFkappaB p50-p50 homodimers act as transcriptional repressors in tolerant CD4+ T cells. J Biol Chem (2003) 1.22
Superantigen-induced regulatory T cells display different suppressive functions in the presence or absence of natural CD4+CD25+ regulatory T cells in vivo. J Immunol (2003) 1.19
A theoretical framework for quantitative analysis of the molecular basis of costimulation. J Immunol (2005) 0.89
A human monoclonal IgG1 potently neutralizing the pro-inflammatory cytokine GM-CSF. Mol Immunol (2006) 0.89
No protection in chickens immunized by the oral or intra-muscular immunization route with Ascaridia galli soluble antigen. Avian Pathol (2013) 0.81
A proteomics approach to the identification of biomarkers for psoriasis utilising keratome biopsy. J Proteomics (2013) 0.81
Translational dermatology in drug discovery: perspectives for integrating humanized xenograft models and experimental clinical studies. Drug Discov Today (2007) 0.79
A highly stable polyethylene glycol-conjugated human single-chain antibody neutralizing granulocyte-macrophage colony stimulating factor at low nanomolar concentration. Protein Eng Des Sel (2006) 0.79
JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis. Am J Pathol (2011) 0.79
Characterization of cellular and humoral immune responses after IBV infection in chicken lines differing in MBL serum concentration. Viral Immunol (2014) 0.76
Cytokine gene expression profiles in chicken spleen and intestinal tissues during Ascaridia galli infection. Vet Parasitol (2014) 0.75